RVMD News and Press, Revolution Medicines Inc - Ordinary Shares

2026-04-14 09:02:21 ET from Guggenheim issued a price target of $175.00 for RVMD on 2026-04-14 11:45:32. The adjusted price target was set to $175.00. At the time of the announcement, RVMD was trading at $136.3. The overall price target consensus is at $129.33 with high ...

2026-04-14 07:15:06 ET H.C. Wainwright analyst issues BUY recommendation for RVMD on April 14, 2026 10:10AM ET. The previous analyst recommendation was Buy. RVMD was trading at $136.3 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2026-04-13 16:10:31 ET More on Revolution Medicines Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside This One Data Readout Could Make Or Break Revolution Medicines Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Healt...

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its intention to offer, subject to market and other conditions, $750 million of common stock ...

2026-04-13 13:02:15 ET from Oppenheimer issued a price target of $165.00 for RVMD on 2026-04-13 15:45:51. The adjusted price target was set to $165.00. At the time of the announcement, RVMD was trading at $134.882. The overall price target consensus is at $124.36 with hi...

2026-04-13 12:35:43 ET Investment Overview The stock of Revolution Medicines, Inc. (RVMD), is up >40% in early trading today, reaching a value of >$131 (at the time of writing), after the Redwood City, California-based biotech company reported positive data from a Phase 3 stud...

2026-04-13 09:29:01 ET More on Revolution Medicines This One Data Readout Could Make Or Break Revolution Medicines Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities REDWOOD CIT...

2026-04-10 08:00:00 ET Introduction While searching Seeking Alpha’s “never covered” list of tickers, I came across a new ETF, the Tema Oncology ETF ( CANC ). Two years ago, within a day, both my father and wife succumbed to their decade-long fights against c...

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluati...